Introduction

In patients with poor cardiac function, low cardiac output syndrome is the most serious problem following cardiac surgery. Thus, many research have been conducted in the field of myocardial protection and different additives to cardioplegic solutions have been tested.

It is well documented that enoximone, levosimendan, and amrinone improve myocardial contractility after cardiopulmonary bypass and in the postoperative period (2,11). However, the role of addition of these drugs to the cardioplegic solution has not been investigated yet. This study is devised to investigate the effects of these drugs to ischemia-reperfusion injury and mechanical dysfunction in reperfusion period, when added to St. Thomas hospital cardioplegic solution. The hypothesis was that pre-treatment with these drugs might be beneficial as they may store more Ca++ in the sarcoplasmic reticulum before cardiac contractility restarts in the reperfusion period.

Material and Methods

All experiments were conducted in compliance with the “Principles of Laboratory Animal Care” and the Guide for Care and Use of Laboratory Animals.

Heart isolation and perfusion

Male and female guinea pigs weighing 500 to 800 g were used in this study (n=6 for each group). The animals were killed by a blow to the head without the use of anesthetic agents. The hearts were excised and immersed immediately in cold (4 °C), heparinized (1000 IU L^{-1}) modified Krebs Henseleit solution, then mounted on a stainless steel cannula of the Langendorff perfusion apparatus, and the hearts were put in a heart chamber in order to prevent drying and keeping the temperature constant. The whole procedure beginning from decapitation to the initiation of perfusion after aortic cannulation was kept less than
60 seconds and otherwise hearts were discarded. Antegrade coronary perfusion was initiated and maintained at a constant perfusion pressure of 85 cm H2O by a modified Krebs Henseleit solution (NaCl 137 mM, KCl 4.5 mM, CaCl2 2.5 mM, NaHCO3 15.5 mM, NaH2PO4 1.2 mM, MgCl2 1.2 mM, and glucose 11.5 mM) and gassed with a mixture of 95% O2 and 5% CO2 to achieve a final oxygen tension above 500 mm Hg. The pH of Krebs Henseleit solution was adjusted to 7.4 when necessary. St. Thomas Hospital cardioplegic solution (NaCl 105 mM, KCl 16 mM, CaCl2 1.2 mM, NaHCO3 10 mM, and MgCl2 10 mM) was filled in the second column of Langendorff apparatus and was not gassed with carbogen. The perfusion solution and cardioplegic solutions were prepared from distilled and de-ionised water and filtered from a 5 (mmembrane. The temperature of the heart and solutions were kept constant at 37 °C by means of a heat exchanger.

A latex balloon inserted to the left ventricle and left intraventricular developed pressure was recorded via P23XL pressure transducer (Grass Instruments). The balloon was filled with 30 mm Hg pressure. The transducer output was displayed on a Grass Model 5 polygraph (Grass Instruments Co. Quincy, Mass. USA). A simultaneous electrogram monitoring was made via two electrodes; one attached to the aortic cannula and the other to the apex of the left ventricle. Coronary effluent was collected for the measurement of coronary flow.

All of the hearts were compared for their pre-ischemic and post-ischemic left ventricular developed pressure, $\frac{+dp}{dt\text{max}}$, $\frac{-dp}{dt\text{max}}$, area under pressure-time curve on beat-by beat-basis heart rate, time to peak pressure, pressure-rate product, rhythm, LDH and CK enzyme leakage, myocardial oxygen consumption, and coronary flow values.

**Experimental protocol**

After a stabilization period of 20 minutes, baseline measurements were performed. The hearts in the control group were arrested with St. Thomas hospital cardioplegic solution for 5 minutes, then perfusion was totally stopped and the hearts were kept in cardioplegic solution for 30 minutes at 37 °C. Afterwards the hearts were reperfused for 10 minutes with Krebs Henseleit solution.

In the positive inotropic agent groups, the experimental protocol was initially the same but either enoximone ($10^{-4}$ mol.L$^{-1}$), or levosimendan ($10^{-5}$ mol.L$^{-1}$), or amrinone ($10^{-5}$ mol.L$^{-1}$) was added to the St. Thomas Hospital cardioplegic solution. These doses were found to be maximum concentrations not deteriorating diastolic function for this preparation in our preliminary experiments. We also had a dose response study in normal and ischemia-reperfusion applied hearts for amrinone and levosimendan that helped us to find the maximum harmless concentrations for this study (16,17). These groups were further perfused with the same concentrations of the inotropic agents in Krebs Henseleit solution for another 5 minutes after the 10th minute of reperfusion.

**Enzyme levels in coronary effluent**

The coronary effluent was collected during the course of the experiment for measurement of the coronary flow rate, and biochemical determination of creatine kinase (CK) (EC 2.7.3.2 Boehringer Mannheim GmbH) and lactate dehydrogenase (LDH) (EC 1.1.1.27 Boehringer Mannheim GmbH) levels as tissue damage markers. Hitachi System 717 automated analyzer was used for CK and LDH assays.

**Oxygen consumption**

For the measurement of oxygen consumption, simultaneous inflow and outflow perfusion solution was collected and measured by Ciba Corning 860 blood gas analysis apparatus.

**Drugs used**

Heparin (Liquemine® Roche, Turkey), amrinone (Sigma, USA), levosimendan (Orion Pharmaceuticals, Finland), enoximone (Merrel, United Kingdom) were used in the study.

**Data analysis**

All data were expressed as the mean ( standard error of the mean. Statistical analysis among groups was performed by one way ANOVA and within groups for initial and reperfusion values by repeated measures ANOVA. Tukey’s Honestly Significance test was used for post hoc comparisons. A p value <0.05 was considered statistically significant.

**Results**

There was no difference between groups in baseline values in any criteria evaluated (p>0.05 for every variables; Table 1-11). All of the hearts arrested within 3 minutes of cardioplegic solution administration and returned spontaneously to sinus rhythm.

**Tab. 1:** Peak systolic pressure values at the initial, reperfusion and inotropic periods.

| Peak systolic pressure (mm Hg) | Initial | Reperfusion | Inotropic |
|--------------------------------|--------|------------|----------|
| St. Thomas                     | 71±6   | 69±6       |          |
| Enoximone                      | 69±10  | 83±10*     | 100±9*   |
| Levosimendan                   | 60±6   | 66±10      | 72±9     |
| Amrinone                       | 59±4   | 56±5       | 64±4     |

*p<0.05
### Tab. 2: \( +\frac{dp}{dt_{\text{max}}}(\text{mm Hg.s}^1) \) at the initial, reperfusion and inotropic periods.

|                | Initial | Reperfusion | Inotropic |
|----------------|---------|-------------|-----------|
| St. Thomas     | 488±168 | 728±249     |           |
| Enoximone      | 791±279 | 1160±284*   | 1411±181* |
| Levosimendan   | 541±176 | 672±205     | 738±159   |
| Amrinone       | 497±95  | 411±99      | 568±116   |

* \( p<0.05 \)

### Tab. 3: \(-\frac{dp}{dt_{\text{max}}}(\text{mm Hg.s}^1) \) at the initial, reperfusion and inotropic periods.

|                | Initial | Reperfusion | Inotropic |
|----------------|---------|-------------|-----------|
| St. Thomas     | 353±112 | 663±260     |           |
| Enoximone      | 402±81  | 418±80      | 997±185*  |
| Levosimendan   | 280±72  | 428±127     | 562±135   |
| Amrinone       | 362±76  | 310±75      | 401±54    |

* \( p<0.05 \)

### Tab. 4: Area under contraction time curve values.

| Area under contraction time curve (mm Hg.s) | Initial | Reperfusion | Inotropic |
|--------------------------------------------|---------|-------------|-----------|
| St. Thomas                                 | 0.039±0.004 | 0.038±0.004 |           |
| Enoximone                                  | 0.032±0.007 | 0.042±0.008 | 0.055±0.007* |
| Levosimendan                               | 0.028±0.005 | 0.031±0.007 | 0.034±0.007 |
| Amrinone                                   | 0.022±0.003 | 0.022±0.004 | 0.025±0.003 |

* \( p<0.05 \)

### Tab. 5: Time to peak pressure.

| Time to peak pressure (s) | Initial | Reperfusion | Inotropic |
|----------------------------|---------|-------------|-----------|
| St. Thomas                 | 0.12±0.01 | 0.13±0.01  |           |
| Enoximone                  | 0.09±0.01 | 0.08±0.01  | 0.09±0.01 |
| Levosimendan               | 0.12±0.01 | 0.10±0.01  | 0.10±0.00 |
| Amrinone                   | 0.09±0.01 | 0.09±0.02  | 0.09±0.01 |

### Tab. 6: Pressure-rate product.

| Pressure rate product (mm Hg × beat.min\(^{-1}\)) | Initial | Reperfusion | Inotropic |
|-------------------------------------------------|---------|-------------|-----------|
| St. Thomas                                      | 99939±38122 | 141986±51558 |           |
| Enoximone                                       | 173808±61894 | 273152±71225 | 327715±52297 |
| Levosimendan                                    | 113893±46214 | 151670±52966 | 167098±40654 |
| Amrinone                                        | 118114±24125 | 84783±22440  | 124838±28661 |

### Tab. 7: Heart rate.

| Heart rate (beat.min\(^{-1}\)) | Initial | Reperfusion | Inotropic |
|--------------------------------|---------|-------------|-----------|
| St. Thomas                      | 193±11  | 185±9       |           |
| Enoximone                       | 218±8   | 225±11      | 228±10    |
| Levosimendan                    | 187±27  | 197±25      | 212±19    |
| Amrinone                        | 237±10  | 167±34      | 217±7     |

### Tab. 8: Creatine kinase enzyme leakage.

| CK (IU.min\(^{-1}\) × g heart\(^{-1}\)) | Initial | Reperfusion | Inotropic |
|------------------------------------------|---------|-------------|-----------|
| St. Thomas                               | 0.02±0.01 | 0.53±0.38  |           |
| Enoximone                                | 0.03±0.01 | 0.47±0.14  | 0.43±0.16 |
| Levosimendan                             | 0.09±0.03 | 0.44±0.15  | 0.35±0.08 |
| Amrinone                                 | 0.08±0.02 | 1.37±0.41  | 0.92±0.35 |

### Tab. 9: Lactate dehydrogenase enzyme leakage.

| LDH (IU.min\(^{-1}\) × g heart\(^{-1}\)) | Initial | Reperfusion | Inotropic |
|------------------------------------------|---------|-------------|-----------|
| St. Thomas                               | 0.03±0.01 | 0.19±0.13  |           |
| Enoximone                                | 0.02±0.01 | 0.11±0.03  | 0.10±0.03 |
| Levosimendan                             | 0.05±0.02 | 0.12±0.03  | 0.10±0.01 |
| Amrinone                                 | 0.06±0.01 | 0.31±0.07  | 0.24±0.06 |

### Tab. 10: Oxygen consumption.

| Oxygen consumption (ml.min\(^{-1}\) × g heart\(^{-1}\)) | Initial | Reperfusion | Inotropic |
|---------------------------------------------------------|---------|-------------|-----------|
| St. Thomas                                               | 1.52±0.12 | 1.49±0.15  |           |
| Enoximone                                                | 1.42±0.10 | 1.48±0.09  | 1.68±0.06 |
| Levosimendan                                             | 1.48±0.21 | 1.96±0.33  | 1.97±0.43 |
| Amrinone                                                 | 2.09±0.45 | 1.89±0.47  | 2.05±0.41 |

### Tab. 11: Coronary flow values.

| Coronary flow (ml.min\(^{-1}\) × g heart\(^{-1}\)) | Initial | Reperfusion | Inotropic |
|-----------------------------------------------------|---------|-------------|-----------|
| St. Thomas                                           | 4.4±0.3 | 4.2±0.5     |           |
| Enoximone                                            | 3.6±0.3 | 3.5±0.2     | 3.9±0.2   |
| Levosimendan                                         | 5.0±0.9 | 6.6±1.3     | 5.5±1.5   |
| Amrinone                                             | 5.5±1.0 | 5.0±1.0     | 5.1±1.1   |
Peak systolic pressure and \( +\text{dp/dt}_{\text{max}} \) values for enoximone group was significantly higher than other groups in the reperfusion and inotropic periods in comparison with other groups (Table 1,2,12). Also, \(-\text{dp/dt}_{\text{max}}\) and area under contraction time curve values for enoximone group was significantly higher than other groups in the inotropic period in comparison with the other groups (Table 3,4). There was no significant difference between groups in CK, and LDH leakage, oxygen consumption, coronary flow values in the reperfusion and inotropic periods (Table 5,6,7). There was also no significant difference between groups in CK, and LDH leakage, oxygen consumption, coronary flow values in the reperfusion and inotropic periods (Table 8,9,10,11).

**Discussion**

We investigated the effects of enoximone, amrinone and levosimendan on ischaemia-induced changes in myocardial function in isolated guinea pig hearts. Enoximone and amrinone selectively inhibit phosphodiesterase enzyme type III in cardiac and vascular smooth muscle cells and results in higher levels of cAMP that promotes Ca\(^{++}\) deposition in sarcoplasmic reticulum by activating Ca\(^{++}\) pump (3). The amount of Ca\(^{++}\) stored in sarcoplasmic reticulum is directly proportional to the amount released to myocardial cytoplasm; thus cardiac contractility increases as the amount of Ca\(^{++}\) released to cytoplasm with action potential increases (4). Levosimendan is a novel inodilator. Its inotropic mechanism is based on calcium sensitization of myofilaments and its vasodilator action is related to the opening of ATP-dependent K-channels (7).

A recent multicenter study clearly showed that enoximone improves exercise capacity in patients with heart failure without increasing adverse events (8). In ischemic human hearts with significant left anterior descending stenoses, hemodynamic effects of intracoronary enoximone injection evaluated with cardiac catheterisation, echocardiography and myocardial perfusion analyses. Shortening of echocontrast dye washout and \( +\text{dp/dt}_{\text{max}} \) increase was found to be significant, which implies the improvement of systolic cardiac functions after intracoronary enoximone injection (10). Rechtman et al. suggested that another phosphodiesterase III inhibitor, amrinone, may be useful in reducing ischaemia-reperfusion injury and speculate that this involves altering ischaemia-induced changes in intracellular Ca\(^{++}\) in the myocytes (12). In isolated perfused rabbit hearts, amrinone reduces both the incidences of ventricular fibrillation and infarct size following coronary occlusion (13). Recently, the effect of different PDE-III inhibitors, including amrinone, was investigated on human neutrophil functions. Chemotaxis, phagocytosis, reactive oxygen species production, intracellular calcium ion concentration, and cyclic adenosine monophosphate levels in neutrophils were measured. Amrinone was shown to scavenge reactive oxygen species at clinically relevant concentrations (9).

The majority of clinically used inotropic drugs act by increasing cytosolic calcium levels, which may hypothetically worsen reperfusion stunning further and cause arrhythmias. Du Toit et al. tested the calcium sensitizer levosimendan in the Langendorff-perfused guinea pig heart, subjected to 40-min low-flow ischemia. Levosimendan improved reperfusion function without promoting arrhythmias in this model. This effect was attributed to opening the K (ATP) channels during ischemia and sensitizing myocardial contractile apparatus rather than elevating cytosolic calcium levels in reperfused hearts (18). Another experimental study showed perfusion of post-ischemic guinea pig hearts with levosimendan was associated with dose- and time-dependent increases in both contractility and speed of relaxation (6). In this study, we encountered the mechanical contraction parameters: peak systolic pressure and \( +\text{dp/dt}_{\text{max}} \) to be significantly higher in reperfusion and inotropic periods in enoximone group when compared with other groups (Table 1,2). \(-\text{dp/dt}_{\text{max}}\) and area under curve values were significantly high in the inotropic period (Table 3,4). However, the comparison of drugs according to the other parameters showed no significant changes. In enoximone group O\(_2\) consumption was found to be less than other groups but the difference was not statistically significant (Table 10).

Shimada et al., using an isolated working heart model studied the effects of dopamine, adrenaline, and noradrenaline pretreatment on ischemia/reperfusion injury. Dopamine and adrenaline had a harmful effect at normothermia (14). We were also worrying about the possibility of harmful effects of positive inotropic agents on myocardial protection. However, our results, including enzyme levels, revealed the harmless impact of enoximone, levosimendan and amrinone on reperfusion injury.

We were unable to find any other study concerning the effects of enoximone, amrinone and levosimendan on reperfusion injury when administered before ischemic arrest. Komai et al. used milrinone and isoproterenol in an isolated working rat heart model. Enrichment of St. Thomas’ hospital solution with milrinone and isoproterenol aggravated reperfusion damage in this study (5). Contrary to this, another phosphodiesterase III-inhibitor (E-1020) was added to Bretschneider’s HTK cardioprotective solution and exerted better myocardial protection in rabbit hearts (19). Similarly, adenosine monophosphate phosphodiesterase inhibitor, DN-9693, was examined in an isolated rabbit heart cardioplegic arrest model and was shown its myocardial protective effect with possible inhibition of leukocyte aggregation (1).

In stunned myocardium, oxygen consumption is relatively high and inotropic agents which act via intracellular increased calcium result in a higher oxygen demand. Theoretically, Ca-sensitization might be a favorable alternative. Sunderdieck et al. compared a Ca\(^{2+}\)-sensitizer (EMD 60263) with enoximone on rabbit hearts during reperfusion after global ischemia. It is concluded that Ca-sensitization
may potentially be a superior method for inotropic support in the postischemic heart (15). However, our study revealed no better preservation with levosimendan rather than enoximone.

In conclusion, the addition of enoximone to St. Thomas hospital cardioplegic solution enhanced myocardial contractility without causing a harmful effect on diastolic function. Our results and previous studies do not clarify the reason why enoximone is superior to other phosphodiesterase inhibitor amrinone and levosimendan with this respect.

References

1. Chang-Chun C, Matsuda H, Sawa Y et al. Effect of a cyclic adenosine mono-phosphate phosphodiesterase inhibitor, DN-9693, on myocardial reperfusion injury. Ann Thorac Surg 1991;52(2):495-9
2. Doyle AR, Dhir AK, Moors AH, Latimer RD. Treatment of perioperative low cardiac output syndrome. Ann Thorac Surg 1995;59(suppl 2):3-14
3. Honerjager P. Pharmacology of bipyridine phosphodiesterase III inhibitors. Am Heart J 1991;121(part 2); 1939-1944
4. Katsung BG, Parmley WW. Cardiac glycosides & other drugs used in congestive heart failure. In: Katzung BG, Parmley WW (ed). Basic and Clinical Pharmacology. Lange, 5th edition. 1996;197-215
5. Komai H, Yamamoto F, Tanaka K et al. Harmful effects of inotropic agents on myocardial protection. Ann Thorac Surg 1991;52(4):927-33
6. Kristof E, Szigeti G, Papp Z et al. The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts. Basic Res Cardiol 1999;94(4):223-30
7. Lehtonen LA. Levosimendan: a parenteral calcium-sensitizing drug with additional vasodilatory properties. Expert Opin Investig Drugs 2001;10(5):955-70
8. Lowes BD, Higinbotham M, Petrovich L et al. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol 2000;36(2):501-8
9. Mikawa K, Akamatsu H, Nishina K et al. The effect of phosphodiesterase III inhibitors on human neutrophil function. Crit Care Med 2000;28(4):1001-5
10. Mitrovic V, Strasser R, Berwing K, Thormann J, Schlepper M. Acute effects of enoximone after intracoronary administration on hemodynamics, myocardial perfusion and regional wall motion. Z Kardiol 1996;85(11):856-67
11. Nijawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34(2):219-28
12. Rechtman MP, Van der Zyp A, Majewski H. Amrinone reduces ischaemia-reperfusion injury in rat heart. Eur J Pharmacol 2000;402(3):255-62
13. Saltman AE, Gaudette GR, Levitsky S, Kruekenkamp IB. Amrinone preconditioning in the isolated perfused rabbit heart. Ann Thorac Surg 2000;70(2):609-13
14. Shimada Y, Yamamoto F, Yamamoto H, Newling R. Is the use of catecholamine before ischemic arrest safe? Effect of catecholamine on rat heart ischemia/reperfusion injury. Jpn J Thorac Cardiovasc Surg 1999;47(7):299-312
15. Sunderdiek U, Korbmacher B, Gams E, Schipke JD. Myocardial efficiency in stunned myocardium. Comparison of Ca (2+)-sensitization and PDE III-inhibitors on energy consumption. Eur J Cardiothorac Surg 2000;18(1):83-9
16. Süzer O, Bozkurt AK, Süzer A, Aykaç Z, Barlas A. Enoximone is more potent inotropic agent than amrinone. Gönül Kalp Damar Cerrahisi Dergisi 1996;4:4-8
17. Süzer O, Bozkurt AK, Süzer A, Aykaç Z, Barlas A. Levosimendan is a more potent inotropic agent than amrinone after ischemia in isolated perfused guinea pig hearts. Br J Anaest 1996;76(suppl 1):A9
18. Du Toit EF, Muller CA, McCarthy J, Opie LH. Levosimendan: effects of a calcium sensitizer on function and arrhythmia’s and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999;290(2):505-14
19. Wang Y, Sunamori M, Suzuki A. Effect of phosphodiesterase III-inhibitor (E-1020) adjunct to Bretschneider’s HTK cardioplegic solution on myocardial preservation in rabbit heart. Thorac Cardiovasc Surg 1996;44(4):167-72

Submitted February 2002. Accepted May 2002.

Cengiz Köksal, M.D.,
P.O.Box 26, Cerrahpasa, 34301-Istanbul/Turkey.
e-mail: cengizkoksal@hotmail.com